Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

核心观点 3 月服装零售表现稳健，终端消费力逐步恢复。3 月社零同比增长 5.9%，环比 1-2 月提速显著，反映出随着政府持续 推出多项消费补贴以及 3 月《提振消费专项行动方案》，消费意愿以及信心持续提升。服装零售同比增长 3.6%，表 现弱于整体消费大盘，主要因为 3 月部分地区天气异常，对板块主要公司春装流水形成影响，但 3 月增速环比 1-2 月 仍提升 0.3pct，反映终端消费力逐步改善。展望未来，4 月北上等核心城市气温转暖，有助春夏装销售增长，整体 来看我们认为服装消费处于复苏过程，服装板块复苏的潜在弹性和改善空间，建议持续关注服装板块的投资机会。 各大品牌 3月线上稳健，关注稳健医疗等数据超预期可能。根据久谦数据，3月服装配饰线上销售额同比增长2.6%， 总体与统计局数据吻合（服装线上同比下降 0.1%），受天气影响，各大服饰品牌 3 月数据环比 1-2 月份有所下降。 1）运动与户外服饰中，FILA、特步等维持良好增长，波司登受益于 3 月气温较低，销售额同比增长超 90%，Q1 同比 增长 13.6%。2）个护行业 3 月受 24 年高基数影响有较为明显的降速，全棉时代/奈丝公主 3 ...

Investment Rating - The industry investment rating is "Overweight" (maintained) [1] Core Viewpoints - The report indicates that the recovery of consumer demand is ongoing, supported by the expansion of the "old-for-new" policy and the restoration of consumer confidence. The food and beverage sector is expected to benefit from upcoming domestic demand expansion policies [4][6] - The report highlights that the liquor industry is at the bottom of its cycle, with a high probability of stable upward movement, making it a suitable time for medium to long-term investment [4] - In the snack segment, companies with channel reforms and overseas market expansion are favored, with recommendations for Ganyuan Food. The beer industry is also expected to improve with the recovery of dining, recommending Qingdao Beer. Additionally, the dairy industry is highlighted for its potential due to fertility policy catalysts and the expected balance in raw milk prices, recommending leading company Yili [4] Summary by Sections Industry Trends - The social retail sales data for March 2025 showed a year-on-year increase of 5.9%, with a month-on-month increase of 1.9 percentage points compared to January-February [5][9] - The food and oil consumption growth rate remains stable, with significant increases in March for food and beverage categories, indicating a recovery in dining and nightlife consumption [5][6] Quarterly Observations - In Q1 2025, social retail sales increased by 4.6% year-on-year, with improvements in dining revenue, reflecting ongoing consumer demand recovery [6][7] - The food and oil category maintained a high growth rate, while beverage and tobacco categories showed month-on-month improvements, driven by improved consumer confidence [6][7] Industry Analysis - Major liquor companies are adjusting their targets and managing channel pressures, leading to a stable transition in the industry. The performance of leading liquor companies is expected to improve in the second half of the year as the base effect diminishes [7] - The snack segment is anticipated to accelerate in Q2, supported by channel reforms and category expansion, maintaining a favorable industry outlook [7]

平安证券指出，随着促进消费政策的不断推出，以及居民收入和信心的逐步恢复，消费复苏将呈现前低 后高的节奏，年内建议关注零食和餐饮产业链的投资机会。休闲零食：零食的渠道红利和产品红利仍 在，一方面新渠道红利尚未结束，另一方面制造型企业不断推出新品抢占消费者心智，行业整体维持高 景气。餐饮产业链：餐饮行业景气度处于底部企稳阶段，预判年内餐饮可能会有小幅度复苏。餐饮相关 产业链如啤酒、调味品、速冻食品等行业可适当关注。 （文章来源：证券时报网） 此外，近日，中共中央办公厅、国务院办公厅印发《提振消费专项行动方案》，提出改革完善促进消费 体制机制，健全和用好宏观政策取向一致性评估工作机制，加强财税、金融、产业、投资等政策与消费 政策的协同，促进同向发力、形成合力，构建更加有利于促消费的政策体系。 机构认为，随着一揽子政策的有序出台，内需有望迎来改善契机。 食品饮料板块15日盘中发力走高，截至发稿，一致魔芋涨超25%，盘中创出新高；欢乐家20%涨停，嘉 必优涨超10%，劲仔食品、安记食品、麦趣尔均涨停，骑士乳业涨超9%。 消息面上，商务部等六部门近日联合印发《关于组织开展"购在中国"系列活动的通知》，部署各地聚焦 首发经 ...

Core Viewpoint - The article discusses the recent performance of the STAR Market Composite Index and highlights the impact of U.S.-China trade policies on the pharmaceutical sector, suggesting potential investment opportunities in innovation, overseas markets, equipment upgrades, and consumer recovery [3][4]. Group 1: Market Performance - As of April 14, 2025, the STAR Market Composite Index rose by 1.13%, with notable increases in stocks such as Yuyuan Pharmaceutical (up 19.99%) and Kexing Pharmaceutical (up 17.23%) [3]. - The STAR Market ETF (Hua Xia) also saw a rise of 1.19%, marking its fifth consecutive increase, with a latest price of 0.94 yuan [3]. - The trading volume for the STAR Market ETF was active, with a turnover rate of 23.24% and a transaction value of 197 million yuan [3]. Group 2: Trade Policy Impact - Following the U.S. government's announcement of a 34% tariff on Chinese goods on April 2, 2025, both countries adjusted their bilateral trade tariffs to 125% as of April 11, 2025 [3]. - The frequent adjustments in tariff policies are expected to disrupt U.S.-China pharmaceutical trade, but companies primarily exporting to markets outside the U.S. may be less affected [3]. - The increased tariffs on U.S. goods could accelerate the import substitution process for high-market-share biopharmaceutical products in China [3]. Group 3: Investment Themes - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [4]. - The "innovation" theme emphasizes investing in globally competitive innovative drugs and promising categories with significant market potential [4]. - The "overseas expansion" theme indicates that there are long-term opportunities in overseas markets [4]. - The "equipment upgrades" theme anticipates increased support for medical equipment updates from central and local government financing [4]. - The "consumer recovery" theme highlights potential rebounds in sectors like ophthalmology, dentistry, and medical aesthetics due to consumer stimulus policies [4]. Group 4: ETF Performance and Metrics - The STAR Market ETF (Hua Xia) has reached a new high in scale at 839 million yuan and a new high in shares at 908 million [4]. - Recent net inflows into the ETF totaled approximately 22.08 million yuan, with a total of 57.84 million yuan net inflow over the past five trading days [4]. - The ETF's management fee is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [5]. - The tracking error for the ETF over the past month is 0.010%, indicating high tracking precision compared to similar funds [5]. Group 5: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the STAR Market Composite Index is 129.12, which is at a historical low, being in the 19.67th percentile over the past year [6]. - The top ten weighted stocks in the STAR Market Composite Index account for 22.34% of the index, with companies like Haiguang Information and Cambricon Technologies among the leaders [6].

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Viewpoints - The ongoing US-China tariff policies are causing disruptions, suggesting a focus on non-US market expansion and import substitution opportunities in the biopharmaceutical sector [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, with companies primarily exporting to markets outside the US being less affected [4][9] - The report emphasizes the potential for domestic products to gain market share in the biopharmaceutical sector due to increased tariffs on US imports [9][10] Summary by Sections Tariff Policy Overview - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [4][5] Biopharmaceutical Sector Insights - The blood products sector is expected to stabilize prices and increase the market share of domestic products due to tariff impacts on imports, particularly for albumin [9] - The medical device sector is anticipated to accelerate domestic substitution due to reliance on North American production, with specific focus on electrophysiology and imaging products [10] - The report suggests monitoring companies such as Palin Bio, Tian Tan Bio, and Huashan Bio for potential growth opportunities in the blood products market [9][10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [12] - Specific companies highlighted for innovation include BeiGene, Dongcheng Pharmaceutical, and others with strong global competitiveness [12] - Companies like Mindray Medical and United Imaging are noted for their potential in overseas markets [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, showing a 49% year-on-year increase in sales [13] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - The report also highlights the potential of companies like East China Pharmaceutical and others in the nuclear medicine sector [17] Market Performance - The biopharmaceutical sector has seen a decline of 5.61% recently, with specific sub-sectors experiencing varying levels of impact [31][44]

Investment Rating - The investment rating for the agriculture, forestry, animal husbandry, and fishery industry is "Positive" (maintained) [1] Core Insights - The report highlights that the recent increase in tariffs imposed by the US on Chinese imports, along with China's retaliatory measures, is expected to positively impact domestic agricultural product prices, particularly pork prices [5][15] - The average price of live pigs in China as of April 6, 2025, is 14.60 yuan/kg, showing a week-on-week increase of 0.05 yuan/kg, indicating a gradual upward trend in pork prices supported by improved demand and reduced supply pressure [6][18] - The report recommends actively allocating investments in the pig farming sector due to its defensive attributes amid macroeconomic shocks and the strengthening investment logic [6][28] Summary by Sections Weekly Observation - The US has imposed a 34% tariff on Chinese imports, leading to a cumulative tariff rate of 54% on Chinese goods, which is expected to benefit domestic agricultural prices [5][15] - The report notes that the dependency of key agricultural products on imports from the US is significant, with soybeans and beef having high foreign dependency rates of 81.49% and 25.22%, respectively [16][17] Weekly Market Performance - The agricultural index outperformed the market by 1.79 percentage points, with the agricultural index rising by 1.51% during the week [32][34] - Key stocks such as Huisheng Biological and Jinhai Biological saw significant gains, with increases of 39.96% and 18.80%, respectively [32][36] Price Tracking - As of April 4, 2025, the average price of live pigs is 14.60 yuan/kg, with a slight increase from the previous week, while the price of piglets has risen to 37.08 yuan/kg [39][40] - The report indicates that the price of beef has also increased, reaching 66.38 yuan/kg, reflecting a positive trend in meat prices [43][46] Recommendations - The report suggests focusing on the pig farming sector, with specific recommendations for companies such as Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [7][28] - In the feed sector, companies like Haida Group and New Hope are recommended due to their potential benefits from the recovery in livestock and poultry production [28]

Group 1 - The retail industry in China shows signs of improvement with a retail prosperity index of 50.5% in April, up 0.3 percentage points month-on-month [1] - The increase in the retail index is driven by seasonal promotions and trade-in activities, indicating a steady rise in consumer vitality [1] - The first quarter of this year saw a significant acceleration in China's consumer market, aided by effective consumption policies and the effects of the Spring Festival holiday [1] Group 2 - Offline consumption has rapidly rebounded, with a year-on-year growth of 14.2% in the offline consumption heat index for the first quarter, an increase of 9.1 percentage points from the previous quarter [3] - In March, offline consumption grew by 20.0% year-on-year, indicating a continuous upward trend [3] - Growth rates for different city tiers in March were 19.6% for first-tier cities, 11.4% for second-tier cities, and 20.2% for third-tier and below [3] Group 3 - The small commodity market's operational heat index increased by 16.3% year-on-year in the first quarter, with March showing a 21.6% increase, reflecting strong demand for daily necessities [5] - The life service consumption heat index rose by 18.3% year-on-year in the first quarter, with a 14.5% increase in March, indicating a recovery in life service consumption [5] - The leisure and catering industries experienced significant growth, with year-on-year increases of 67.6% and 14.5%, respectively [5] Group 4 - The Qingming Festival saw a surge in travel enthusiasm, with internet search heat for related keywords increasing over fourfold recently [7] - Diverse consumption scenarios such as flower viewing, suburban travel, and cultural experience tours are further releasing consumer potential, contributing to the ongoing recovery of the domestic market [7]

Investment Rating - The industry rating is "Outperform the Market" [7][57] Core Views - The report emphasizes that the international environment is turbulent, and domestic demand promotion may be the main theme for the market [3][13] - The SW Baijiu index PE-TTM is currently at 19.97, which is at a very low percentile of 8.93% over the past 10 years, indicating a strong safety margin [3][14] - The report suggests that the white liquor industry is expected to enter a healthier new phase as channel inventory is continuously digested during peak seasons [14] - The report highlights the importance of rational target setting for liquor companies in 2025, which is crucial for the industry's cyclical trends [14] Summary by Sections Baijiu - The report recommends focusing on companies like Moutai and Wuliangye, which have price stabilization and market share enhancement capabilities [3][14] - The report notes that the white liquor sector experienced a slight decline of 0.71% this week, with some companies like Huangtai and Jinhui showing gains [12] Beer - Key recommendations include Qingdao Beer and Yanjing Beer, which are expected to benefit from high-end strategies and efficiency reforms [19][15] - The report anticipates stable beer sales in 2025, with revenue growth driven by structural upgrades [18] Soft Drinks - The report suggests focusing on East Peak Beverage, which is exploring a second growth curve, and Xiangpiaopiao, which has positive fundamentals [20][19] Pre-mixed Drinks - The report identifies Baijun as a leading company in the pre-mixed drinks sector, with a favorable PE ratio and significant growth potential [23][22] Dairy Products - The report recommends Yili, a national dairy giant, focusing on profit-oriented strategies and product structure optimization [24][24] Snacks - The report highlights the snack sector's resilience, suggesting companies like Ximai Foods and Ganyuan Foods as potential investment opportunities [27][29] Condiments & Catering - Key recommendations include Angel Yeast, which is expected to benefit from strong domestic sales and overseas growth [34][35] Baking Supply Chain - The report recommends Lihai Foods and Huirong Technology, which are expected to show strong performance due to market dynamics [39][39] Health Products & Sweeteners - The report emphasizes the growth potential in the health products sector, particularly for companies like Bailong Chuangyuan and Huakang [40][32] Catering - Recommendations include Yum China and other companies that are expected to benefit from supply chain optimization and brand development [41][45] Pet Industry - The report suggests focusing on companies like Zhongchong and Peidi, which are expected to benefit from both domestic and international market dynamics [46][49] Gold & Jewelry - The report recommends companies like Chaohongji and Zhou Dashi, which are expected to perform well amid high gold prices [50][50]